A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies

被引：0
|
作者：
Sessa, C.
Sharma, S. K.
Britten, C. D.
Vogelzang, N. J.
Bhalla, K. N.
Mita, M. M.
Pluard, T. J.
Stiegler, P.
Quadt, C.
Shapiro, G. I.
机构：
[1] IOSI, Bellinzona, Switzerland
[2] Nevada Canc Inst, Las Vegas, NV USA
[3] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[4] Med Coll Georgia, Augusta, GA 30912 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Novartis Pharmaceut, Florham Pk, NJ USA
[8] Novartis Pharmaceut, Basel, Switzerland
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3532
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Yusuke Onozawa
    Nozomu Fuse
    Takayuki Yoshino
    Kentaro Yamazaki
    Junichiro Watanabe
    Mikhail Akimov
    Matthew Robson
    Narikazu Boku
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 629 - 636
  • [2] Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Onozawa, Yusuke
    Fuse, Nozomu
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Watanabe, Junichiro
    Akimov, Mikhail
    Robson, Matthew
    Boku, Narikazu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 629 - 636
  • [3] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Shapiro, Geoffrey I.
    Bhalla, Kapil N.
    Britten, Carolyn
    Jacks, Karen S.
    Mita, Monica
    Papadimitrakopoulou, Vali
    Pluard, Tim
    Samuel, Thomas A.
    Akimov, Mikhail
    Quadt, Cornelia
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Bailey, Stuart
    Chica, Sandra
    Banerji, Udai
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
  • [4] A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Jones, Suzanne F.
    Hart, Lowell
    Pant, Shubham
    Moyhuddin, Adil
    Lane, Cassie M.
    Earwood, Chris
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William C.
    Thompson, Dana
    Infante, Jeffrey R.
    CANCER INVESTIGATION, 2015, 33 (10) : 477 - 482
  • [5] Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors
    Pant, Shubham
    Hart, Lowell L.
    Bendell, Johanna C.
    Infante, Jeffrey R.
    Jones, Suzanne Fields
    Mohyuddin, Adil
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William Charles
    Thompson, Dana Shelton
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors
    Bendell, Johanna C.
    Hart, Lowell L.
    Pant, Shubham
    Infante, Jeffrey R.
    Jones, Suzanne Fields
    Mohyuddin, Adil
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William Charles
    Thompson, Dana Shelton
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] AUY922, a novel HSP90 inhibitor: Final results of a First-in-human study in patients with advanced solid malignancies.
    Samuel, T. A.
    Sessa, C.
    Britten, C.
    Milligan, K. S.
    Mita, M. M.
    Banerji, U.
    Pluard, T. J.
    Stiegler, P.
    Quad, C.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma
    Kosovec, Juliann E.
    Zaidi, Ali H.
    Kelly, Lori A.
    Rotoloni, Christina L.
    Vytlacil, Christopher
    DiCarlo, Christina
    Matsui, Daisuke
    Komatsu, Yoshihiro
    Boyd, Natalie H.
    Omstead, Ashten
    Kolano, Elena L.
    Biederman, Robert W. W.
    Finley, Gene
    Silverman, Jan F.
    Landreneau, Rodney J.
    Jobe, Blair A.
    ANNALS OF SURGERY, 2016, 264 (02) : 297 - 304
  • [9] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    D. J. Renouf
    D. Hedley
    M. K. Krzyzanowska
    M. Schmuck
    L. Wang
    M. J. Moore
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 541 - 545
  • [10] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    Renouf, D. J.
    Hedley, D.
    Krzyzanowska, M. K.
    Schmuck, M.
    Wang, L.
    Moore, M. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 541 - 545
12345